Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction

Osteoarthritis Cartilage. 2019 Jun;27(6):965-976. doi: 10.1016/j.joca.2019.01.009. Epub 2019 Feb 1.

Abstract

Objective: The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that integrates nutrients to execute cell growth. We hypothesized that mTOR is influential in the intervertebral disc-largest avascular, low-nutrient organ. Our objective was to identify the optimal mTOR inhibitor for treating human degenerative disc disease.

Design: mTOR complex 1 (mTORC1) regulates p70/ribosomal S6 kinase (p70/S6K), negatively regulates autophagy, and is controlled by Akt. Akt is controlled by phosphatidylinositol 3-kinase (PI3K) and mTOR complex 2 (mTORC2). mTORC1 inhibitors-rapamycin, temsirolimus, everolimus, and curcumin, mTORC1&mTORC2 inhibitor-INK-128, PI3K&mTOR inhibitor-NVP-BEZ235, and Akt inhibitor-MK-2206-were applied to human disc nucleus pulposus (NP) cells. mTOR signaling, autophagy, apoptosis, senescence, and matrix metabolism were evaluated.

Results: mTORC1 inhibitors decreased p70/S6K but increased Akt phosphorylation, promoted autophagy with light chain 3 (LC3)-II increases and p62/sequestosome 1 (p62/SQSTM1) decreases, and suppressed pro-inflammatory interleukin-1 beta (IL-1β)-induced apoptotic terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positivity (versus rapamycin, 95% confidence interval (CI) -0.431 to -0.194; temsirolimus, 95% CI -0.529 to -0.292; everolimus, 95% CI -0.477 to -0.241; curcumin, 95% CI -0.248 to -0.011) and poly (ADP-ribose) polymerase (PARP) and caspase-9 cleavage, senescent senescence-associated beta-galactosidase (SA-β-gal) positivity (versus rapamycin, 95% CI -0.437 to -0.230; temsirolimus, 95% CI -0.534 to -0.327; everolimus, 95% CI -0.485 to -0.278; curcumin, 95% CI -0.210 to -0.003) and p16/INK4A expression, and catabolic matrix metalloproteinase (MMP) release and activation. Meanwhile, dual mTOR inhibitors decreased p70/S6K and Akt phosphorylation without enhanced autophagy and suppressed apoptosis, senescence, and matrix catabolism. MK-2206 counteracted protective effects of temsirolimus. Additional disc-tissue analysis found relevance of mTOR signaling to degeneration grades.

Conclusion: mTORC1 inhibitors-notably temsirolimus with an improved water solubility-but not dual mTOR inhibitors protect against inflammation-induced apoptosis, senescence, and matrix catabolism in human disc cells, which depends on Akt and autophagy induction.

Keywords: Akt; Autophagy; Intervertebral disc; Mammalian target of rapamycin (mTOR); Nucleus pulposus cells; Spine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Apoptosis / drug effects*
  • Autophagy / drug effects*
  • Benzoxazoles / pharmacology
  • Cellular Senescence / drug effects*
  • Curcumin / pharmacology
  • Everolimus / pharmacology
  • Extracellular Matrix / drug effects*
  • Extracellular Matrix / metabolism
  • Female
  • Heterocyclic Compounds, 3-Ring / pharmacology
  • Humans
  • Imidazoles / pharmacology
  • Inflammation
  • Male
  • Matrix Metalloproteinases / drug effects
  • Matrix Metalloproteinases / metabolism
  • Mechanistic Target of Rapamycin Complex 1 / antagonists & inhibitors*
  • Mechanistic Target of Rapamycin Complex 1 / metabolism
  • Mechanistic Target of Rapamycin Complex 2 / antagonists & inhibitors
  • Mechanistic Target of Rapamycin Complex 2 / metabolism
  • Microtubule-Associated Proteins / drug effects
  • Microtubule-Associated Proteins / metabolism
  • Middle Aged
  • Nucleus Pulposus / cytology
  • Nucleus Pulposus / drug effects*
  • Nucleus Pulposus / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins c-akt / drug effects*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Pyrimidines / pharmacology
  • Quinolines / pharmacology
  • Ribosomal Protein S6 Kinases, 70-kDa / drug effects
  • Ribosomal Protein S6 Kinases, 70-kDa / metabolism
  • Sequestosome-1 Protein / drug effects
  • Sequestosome-1 Protein / metabolism
  • Sirolimus / analogs & derivatives
  • Sirolimus / pharmacology
  • beta-Galactosidase / drug effects
  • beta-Galactosidase / metabolism

Substances

  • Benzoxazoles
  • Heterocyclic Compounds, 3-Ring
  • Imidazoles
  • MAP1LC3B protein, human
  • MK 2206
  • Microtubule-Associated Proteins
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Quinolines
  • SQSTM1 protein, human
  • Sequestosome-1 Protein
  • temsirolimus
  • Everolimus
  • Mechanistic Target of Rapamycin Complex 1
  • Mechanistic Target of Rapamycin Complex 2
  • Proto-Oncogene Proteins c-akt
  • Ribosomal Protein S6 Kinases, 70-kDa
  • GLB1 protein, human
  • beta-Galactosidase
  • Matrix Metalloproteinases
  • Curcumin
  • sapanisertib
  • dactolisib
  • Sirolimus